AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33448607 — intervention group
Group type: EXPERIMENTAL
Intervention: LATP biopsy
Number of subjects: 1218
Study 35355249 — intervention group
Group type: EXPERIMENTAL
Intervention: KHKi 50 mg once daily
Number of subjects: 12
Study 35355249 — intervention group
Group type: EXPERIMENTAL
Intervention: KHKi 280 mg once daily
Number of subjects: 12
Study 35355249 — intervention group
Group type: EXPERIMENTAL
Intervention: KHKi alone (100–600 mg)
Number of subjects: 12
Study 35355249 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone (20 mg single dose)
Number of subjects: 12
Study 35355249 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based analysis
Number of subjects: 12
Study 34428929 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI treatment
Number of subjects: 177
Study 34428929 — intervention group
Group type: COMPARATOR
Intervention: ARB treatment
Number of subjects: 177
Study 34428929 — intervention group
Group type: COMPARATOR
Intervention: non-ACE/ARB treatment
Number of subjects: 177
Study 34396911 — intervention group
Group type: EXPERIMENTAL
Intervention: LEF plus low-dose prednisone
Number of subjects: 108
Study 34396911 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 108
Study 32242018 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-norepinephrine reuptake inhibitor (SNRI) treatment
Number of subjects: 424
Study 32242018 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 424
Study 32242018 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR56 peptide agonists
Number of subjects: 424
Study 32242018 — intervention group
Group type: COMPARATOR
Intervention: Gpr56 knockdown in mouse PFC
Number of subjects: 424
Study 35199834 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d DHA (experimental group: EXP)
Number of subjects: 9
Study 35199834 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/d DHA (standard group: STD)
Number of subjects: 9
Study 34414609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble machine learning model
Number of subjects: 33657
Study 34414609 — intervention group
Group type: COMPARATOR
Intervention: Random forest
Number of subjects: 33657
Study 34414609 — intervention group
Group type: COMPARATOR
Intervention: Deep neural network
Number of subjects: 33657
Study 34414609 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression
Number of subjects: 33657
Study 34414609 — intervention group
Group type: COMPARATOR
Intervention: Adaboost
Number of subjects: 33657
Study 32907614 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+pred
Number of subjects: 92
Study 32907614 — intervention group
Group type: COMPARATOR
Intervention: MTX+plac
Number of subjects: 92
Study 36185549 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg plus topical corticosteroids (TCS)
Number of subjects: 29
Study 36185549 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg plus topical corticosteroids (TCS)
Number of subjects: 29
Study 36185549 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids (TCS)
Number of subjects: 29
Study 36105447 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaha system continuous nursing intervention
Number of subjects: 76
Study 36105447 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative nursing intervention
Number of subjects: 76
Study 32166837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure for 12 weeks
Number of subjects: 72
Study 32166837 — intervention group
Group type: COMPARATOR
Intervention: No continuous positive airway pressure (Control)
Number of subjects: 72
Study 36074627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine lozenge
Number of subjects: 67
Study 36074627 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 67
Study 34391301 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TM)
Number of subjects: 45
Study 34391301 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy (ME) technique
Number of subjects: 45
Study 34391301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 32843762 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Tagatose and Xylitol (combined)
Number of subjects: 29
Study 32843762 — intervention group
Group type: COMPARATOR
Intervention: D-Tagatose
Number of subjects: 29
Study 32843762 — intervention group
Group type: COMPARATOR
Intervention: Xylitol
Number of subjects: 29
Study 35320214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 120
Study 35320214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33308328 — intervention group
Group type: EXPERIMENTAL
Intervention: Millet couscous (self-made)
Number of subjects: 14
Study 33308328 — intervention group
Group type: EXPERIMENTAL
Intervention: Millet foods (millet couscous, millet thick porridge) and wheat couscous
Number of subjects: 14
Study 33308328 — intervention group
Group type: EXPERIMENTAL
Intervention: All foods tested (millet couscous, millet thick porridge, wheat couscous, white rice)
Number of subjects: 14
Study 32198095 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 60
Study 32198095 — intervention group
Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 60
Study 35768708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioheart Sirolimus-Eluting Bioresorbable Vascular Scaffold (BRS)
Number of subjects: 46
Study 34941547 — intervention group
Group type: EXPERIMENTAL
Intervention: QualityIQ tool (gamified approach)
Number of subjects: 120
Study 34941547 — intervention group
Group type: COMPARATOR
Intervention: Non-CME study arm
Number of subjects: 120
Study 35909264 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (0.5 mg TID up-titrated to 1.5 mg TID)
Number of subjects: 114
Study 35909264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 35909264 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 114
Study 32394733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 153
Study 32394733 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study 32060506 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour introductory training intervention
Number of subjects: 34
Study 35411924 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (SYN) containing inulin (4 g) and Lactobacillus rhamnosus GG (>1 × 10^7 CFU/mL)
Number of subjects: 30
Study 35411924 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (CON)
Number of subjects: 30
Study 35411924 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (SYN)
Number of subjects: 30
Study 35172560 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 240
Study 35172560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab injections
Number of subjects: 240
Study 35172560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypogammaglobulinemia <6 g/L or <4 g/L
Number of subjects: 240
Study 35172560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypogammaglobulinemia
Number of subjects: 240
Study 35172560 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious events, neutropenia, and CD4 lymphopenia
Number of subjects: 240
Study 32518101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 45
Study 32518101 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 45
Study 35650426 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial imatinib therapy
Number of subjects: 1369
Study 35650426 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive scoring systems for MMR and MR4
Number of subjects: 1369
Study 32975880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare arm
Number of subjects: 300
Study 32975880 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer cotton shirt sleeve (1 mm)
Number of subjects: 300
Study 32975880 — intervention group
Group type: EXPERIMENTAL
Intervention: Two layers sleeve (cotton shirt and polar fabric sweater, 3 mm)
Number of subjects: 300
Study 32975880 — intervention group
Group type: EXPERIMENTAL
Intervention: Two layers sleeve (cotton shirt and thick cardigan, 4 mm)
Number of subjects: 300
Study 33099298 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase (ALP) levels
Number of subjects: 14393
Study 35230558 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional change (raised legs position)
Number of subjects: 31
Study 35230558 — intervention group
Group type: COMPARATOR
Intervention: PEEP
Number of subjects: 31
Study 35230558 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 31
Study 33140685 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular and surgical cardiovascular procedures
Number of subjects: 852
Study 34127095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (3-12 mg/d, 3-6 mg/d, or 6-12 mg/d for 3 weeks)
Number of subjects: 1012
Study 34127095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 1012
Study 34127095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study 34766785 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone breathalyzer device/app
Number of subjects: 99
Study 34766785 — intervention group
Group type: EXPERIMENTAL
Intervention: app that estimates BAC based on factors including sex, weight, number/types of drinks over time
Number of subjects: 99
Study 34766785 — intervention group
Group type: EXPERIMENTAL
Intervention: self-text messaging after each drink
Number of subjects: 99
Study 34766785 — intervention group
Group type: EXPERIMENTAL
Intervention: combined mobile technology intervention
Number of subjects: 99
Study 34766785 — intervention group
Group type: COMPARATOR
Intervention: laboratory alcohol self-administration
Number of subjects: 99
Study 33275087 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted modified LIFT
Number of subjects: 60
Study 33275087 — intervention group
Group type: COMPARATOR
Intervention: Incision thread drawing
Number of subjects: 60
Study 35182042 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) galidesivir, doses 0.3 to 10 mg/kg
Number of subjects: 126
Study 35182042 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) galidesivir, doses 5 to 20 mg/kg
Number of subjects: 126
Study 35182042 — intervention group
Group type: COMPARATOR
Intervention: IM galidesivir with lidocaine, single day dosing and 7-day dosing
Number of subjects: 126
Study 35182042 — intervention group
Group type: COMPARATOR
Intervention: IV galidesivir, single ascending doses
Number of subjects: 126
Study 32770757 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release naltrexone (XR‐NTX)
Number of subjects: 35
Study 32770757 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 35
Study 36343645 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (10-360 mg once daily for 14 days)
Number of subjects: 71
Study 36343645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 36343645 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (≥40 mg once daily for 14 days)
Number of subjects: 71
Study 35634085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon bone setting technique combined with sports training
Number of subjects: 50
Study 35634085 — intervention group
Group type: COMPARATOR
Intervention: Intermediate frequency electrotherapy combined with forearm brace fixation
Number of subjects: 50
Study 32681304 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced survivorship care plan (ESCP) with a link to Patient Education Resources for Couples (PERC)
Number of subjects: 62
Study 32681304 — intervention group
Group type: COMPARATOR
Intervention: Standard survivorship care plan (SCP) with a link to general PC information
Number of subjects: 62
Study 32046452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily + COC containing drospirenone for 21 days
Number of subjects: 300
Study 32046452 — intervention group
Group type: COMPARATOR
Intervention: COC containing drospirenone for 21 days + placebo
Number of subjects: 300
Study 32046452 — intervention group
Group type: COMPARATOR
Intervention: Placebo similar to COC + placebo similar to fluoxetine
Number of subjects: 300
Study 35926795 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular Injection (PAI)
Number of subjects: 180
Study 35926795 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI + Patient‐Controlled Epidural Analgesia (PCEA) with 0.06% bupivacaine
Number of subjects: 180
Study 35926795 — intervention group
Group type: COMPARATOR
Intervention: Patient‐Controlled Epidural Analgesia (PCEA) without intrathecal opioids
Number of subjects: 180
Study 33440017 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 625
Study 33440017 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 625
Study 32201400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nori (dried laver) - 1.76 grams per day for 10 weeks
Number of subjects: 89
Study 32201400 — intervention group
Group type: COMPARATOR
Intervention: Control group - usual diet
Number of subjects: 89
Study 33205362 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg with ethanol
Number of subjects: 19
Study 33205362 — intervention group
Group type: COMPARATOR
Intervention: Daridorexant 50 mg alone
Number of subjects: 19
Study 33205362 — intervention group
Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 19
Study 33205362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 34932140 — intervention group
Group type: EXPERIMENTAL
Intervention: SMaRT group intervention (10-week symptom-management intervention including group support, education, pelvic floor muscle exercises)
Number of subjects: 63
Study 34932140 — intervention group
Group type: EXPERIMENTAL
Intervention: SMaRT group intervention
Number of subjects: 63
Study 34932140 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual group
Number of subjects: 63
Study 33576510 — intervention group
Group type: EXPERIMENTAL
Intervention: DVI model
Number of subjects: 247
Study 33576510 — intervention group
Group type: EXPERIMENTAL
Intervention: dosiomic model
Number of subjects: 247
Study 33576510 — intervention group
Group type: EXPERIMENTAL
Intervention: hybrid model
Number of subjects: 247
Study 32621045 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 4672
Study 34651611 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing surgical mask (SM)
Number of subjects: 33
Study 34651611 — intervention group
Group type: COMPARATOR
Intervention: No surgical mask (no-SM)
Number of subjects: 33
Study 34531206 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick-Wee method (suprapubic stimulation with cold saline-soaked gauze)
Number of subjects: 230
Study 34531206 — intervention group
Group type: COMPARATOR
Intervention: Bladder stimulation (pubic tapping alternating with lumbar massage)
Number of subjects: 230
Study 34531206 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick-Wee method
Number of subjects: 230
Study 34531206 — intervention group
Group type: COMPARATOR
Intervention: Bladder stimulation
Number of subjects: 230
Study 34098009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-delivered cognitive-motor program (120 min per week balance, strength and cognitive training)
Number of subjects: 93
Study 34098009 — intervention group
Group type: COMPARATOR
Intervention: Control group (received monthly phone calls and health fact sheets)
Number of subjects: 93
Study 32184086 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplanted teeth with open apices
Number of subjects: 36
Study 32184086 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of root development during follow-up
Number of subjects: 36
Study 32184086 — intervention group
Group type: COMPARATOR
Intervention: Distant transplantations
Number of subjects: 36
Study 32184086 — intervention group
Group type: COMPARATOR
Intervention: 1-rooted teeth
Number of subjects: 36
Study 32184086 — intervention group
Group type: COMPARATOR
Intervention: Premolars
Number of subjects: 36
Study 32184086 — intervention group
Group type: COMPARATOR
Intervention: Teeth not stored in extraoral media
Number of subjects: 36
Study 32184086 — intervention group
Group type: COMPARATOR
Intervention: Teeth transplanted later during the study period
Number of subjects: 36
Study 33319753 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 1114
Study 33319753 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 1114
Study 36101806 — intervention group
Group type: EXPERIMENTAL
Intervention: CBL teaching mode
Number of subjects: 86
Study 36101806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 32762161 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole and spironolactone
Number of subjects: 75
Study 32762161 — intervention group
Group type: EXPERIMENTAL
Intervention: gonadotrophin releasing hormone analogue (GnRHa)
Number of subjects: 75
Study 32762161 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 75
Study 32762161 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole and GnRHa
Number of subjects: 75
Study 35487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer gambling message condition (yellow version)
Number of subjects: 1509
Study 35487229 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1509
Study 35487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer gambling message condition
Number of subjects: 1509
Study 35606739 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion therapy
Number of subjects: 250
Study 35606739 — intervention group
Group type: COMPARATOR
Intervention: Photon or proton radiotherapy
Number of subjects: 250
Study 33166858 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam packing (GPG)
Number of subjects: 57
Study 33166858 — intervention group
Group type: COMPARATOR
Intervention: Non-gelfoam packing (NGPG)
Number of subjects: 57
Study 33678106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at weeks 0, 4, 16, and 28
Number of subjects: 575
Study 33678106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 4
Number of subjects: 575
Study 33678106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 16
Number of subjects: 575
Study 33678106 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI <50 at week 16
Number of subjects: 575
Study 34479640 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted BREATHE intervention for PTSD
Number of subjects: 0
Study 34479640 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37103690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% plus nitrogen plasma therapy
Number of subjects: 0
Study 37103690 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 4% alone (Control)
Number of subjects: 0
Study 32958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Go Wish intervention for patients and their relatives
Number of subjects: 135
Study 32958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Go Wish intervention for patients alone
Number of subjects: 135
Study 32958487 — intervention group
Group type: COMPARATOR
Intervention: Standardised information on advance directives (usual care)
Number of subjects: 135
Study 35483387 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab once every 6 weeks
Number of subjects: 499
Study 35483387 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab once every 4 weeks
Number of subjects: 499
Study 33753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic hand hygiene monitoring systems (EHHMSs)
Number of subjects: 5
Study 33753120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality stepped-wedge cluster randomized controlled trial design
Number of subjects: 5
Study 33753120 — intervention group
Group type: COMPARATOR
Intervention: General EHHMS implementation
Number of subjects: 5
Study 35133057 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance and Balance Training (PRBT) for 26 weeks
Number of subjects: 245
Study 35133057 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 245
Study 33097414 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus BSC
Number of subjects: 420
Study 33097414 — intervention group
Group type: COMPARATOR
Intervention: BSC
Number of subjects: 420
Study 35167999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prickly Pear juice (250 mL; 45 mg betalain content; reduced fiber)
Number of subjects: 17
Study 35167999 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (water-based)
Number of subjects: 17
Study 33711412 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 46
Study 33711412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33038062 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 100 mg
Number of subjects: 190
Study 33038062 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 200 mg
Number of subjects: 190
Study 33038062 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 400/200 mg
Number of subjects: 190
Study 33038062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 33038062 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 100 mg (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190
Study 33038062 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 200 mg (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190
Study 33038062 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 400/200 mg (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190
Study 33038062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190
Study 32521358 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program (4-week, 3 sessions per week via videoconference)
Number of subjects: 162